Mario Fernández-Zertuche

Prof. Mario Fernández-Zertuche


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AAArmando Antillón
Armando Antillón
AVAlexander H. de Vries
Alexander H. de Vries
MEMarcel Espinosa-Caballero
Marcel Espinosa-Caballero
JFJosé Marcos Falcón-González
José Marcos Falcón-González
DRDavid Flores Romero
David Flores Romero
IOIván Ortega-Blake
Iván Ortega-Blake
Amphotericin B is the most potent antimycotic known to date. However due to its large collateral toxicity, its use, although long standing, had been limited. Many attempts have been made to produce derivatives with reduced collateral damage. The molecular mechanism of polyene has also been closely studied for this purpose and understanding it would contribute to the development of safe derivatives. Our study examined polyene action, including chemical synthesis, electrophysiology, pharmacology, toxicology and molecular dynamics. The results were used to support a novel Amphotericin B derivative with increased selectivity: L-histidine methyl ester of Amphotericin B. We found that this derivative has the same form of action as Amphotericin B, i.e. pore formation in the cell membrane. Its reduced dimerization in solution, when compared to Amphotericin B, is at least partially responsible for its increased selectivity. Here we also present the results of preclinical tests, which show that the derivative is just as potent as Amphotericin B and has increased safety.

20 October 2011 in Molecules
Verified
Journal Article
Open access
PDF file
RMRosmarbel Morales-Nava
Rosmarbel Morales-Nava
MFMario Fernández-Zertuche
Mario Fernández-Zertuche
MOMario Ordóñez
Mario Ordóñez
A microwave assisted method for the synthesis of some typical 4-substituted oxazolidinone chiral auxiliaries used in asymmetric synthesis is reported in this work. Under these conditions, treatment of (S)-phenylalaninol, (S)-phenylglycinol, (S)-valinol and (1S, 2R)-norephedrine with ethyl carbonate or carbon disulfide under the appropriate and specific microwave reaction conditions, led to an efficient synthesis of some oxazolidin-2-ones, oxazolidine-2-thiones and thiazolidine-2-thiones. The methodology reported in this paper provides these chiral auxiliaries with improved yields and a remarkable reduction on the reaction times, particularly in the case of thiazolidine-2-thiones, as compared with the conventional methods. All the auxiliaries prepared here show spectroscopic data in full agreement with those previously reported in the literature.

9 May 2018 in Molecules
Verified
Journal Article
Open access
PDF file
ETErika Tovar-Gudiño
Erika Tovar-Gudiño
JGJ. Alberto Guevara-Salazar
J. Alberto Guevara-Salazar
JBJosé Raúl Bahena-Herrera
José Raúl Bahena-Herrera
JTJosé G. Trujillo-Ferrara
José G. Trujillo-Ferrara
ZMZuleyma Martínez-Campos
Zuleyma Martínez-Campos
MFMario Fernández-Zertuche
Mario Fernández-Zertuche
γ-Aminobutyric acid (GABA) is the most important inhibitory neurotransmitter in the central nervous system, and a deficiency of GABA is associated with serious neurological disorders. Due to its low lipophilicity, there has been an intensive search for new molecules with increased lipophilicity to cross the blood-brain barrier to raise GABA concentrations. We have designed and evaluated in vitro and in silico some new analogues of GABA, where the nitrogen atom at the γ-position is embedded in heterocyclic scaffolds and determined their inhibitory potential over the GABA-AT enzyme from Pseudomonas fluorescens. These modifications lead to compounds with inhibitory activity as it occurs with compounds 18a and 19a. The construction of Pseudomonas fluorescens and human GABA-AT models were carried out by homology modeling. Docking assays were done for these compounds over the GABA-AT enzyme models where 19a showed a strong interaction with both GABA-AT enzymes.

17 June 2019 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
ZMZuleyma Martínez-Campos
Zuleyma Martínez-Campos
NPNina Pastor
Nina Pastor
KPKayim Pineda-Urbina
Kayim Pineda-Urbina
ZGZeferino Gómez-Sandoval
Zeferino Gómez-Sandoval
MFMario Fernández-Zertuche
Mario Fernández-Zertuche
RHRodrigo Said Razo Hernández
Rodrigo Said Razo Hernández

15 November 2018 in Molecules
Verified
Journal Article
Open access
PDF file
JRJosue Rodriguez
Josue Rodriguez
ETErika Tovar-Gudiño
Erika Tovar-Gudiño
JGJ. Alberto Guevara-Salazar
J. Alberto Guevara-Salazar
RHRodrigo Said Razo Hernández
Rodrigo Said Razo Hernández
ÁSÁngel Santiago
Ángel Santiago
MFMario Fernández-Zertuche
Mario Fernández-Zertuche
We have previously reported the synthesis, in vitro and in silico activities of new GABA analogues as inhibitors of the GABA-AT enzyme from Pseudomonas fluorescens, where the nitrogen atom at the γ-position is embedded in heterocyclic scaffolds. With the goal of finding more potent inhibitors, we now report the synthesis of a new set of GABA analogues with a broader variation of heterocyclic scaffolds at the γ-position such as thiazolidines, methyl-substituted piperidines, morpholine and thiomorpholine and determined their inhibitory potential over the GABA-AT enzyme from Pseudomonas fluorescens. These structural modifications led to compound 9b which showed a 73% inhibition against this enzyme. In vivo studies with PTZ-induced seizures on male CD1 mice show that compound 9b has a neuroprotective effect at a 0.50 mmole/kg dose. A QSAR study was carried out to find the molecular descriptors associated with the structural changes in the GABA scaffold to explain their inhibitory activity against GABA-AT. Employing 3D molecular descriptors allowed us to propose the GABA analogues enantiomeric active form. To evaluate the interaction with Pseudomonas fluorescens and human GABA-AT by molecular docking, the constructions of homology models was carried out. From these calculations, 9b showed a strong interaction with both GABA-AT enzymes in agreement with experimental results and the QSAR model, which indicates that bulky ligands tend to be the better inhibitors especially those with a sulfur atom on their structure.

20 July 2016 in Organic Process Research & Development
Verified
Journal Article
Closed access
JFJosé David Flores-Romero
José David Flores-Romero
JRJosue Rodriguez
Josue Rodriguez
MLManuel López-Ortiz
Manuel López-Ortiz
RMRicardo Magaña
Ricardo Magaña
IOIván Ortega-Blake
Iván Ortega-Blake
MFMario Fernández-Zertuche
Mario Fernández-Zertuche